Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GNS-211-D
- Development stage
- Preclinical
- Lead developer
- Genewon Science
- Modality
- Small Molecules
01
Overview
GNS-211-D is a small molecule drug candidate being developed by Genuone Sciences for the treatment of diabetes mellitus. It is classified as an "improved drug" (개량신약) within the South Korean regulatory framework, a category that typically includes drugs with modified formulations, new salts, or other incremental improvements over existing therapies to enhance efficacy, safety, or patient compliance. The drug is currently in the early stages of development within Genuone's endocrine and metabolic disease pipeline. Specific details regarding its active pharmaceutical ingredient, biological target, and mechanism of action have not been publicly disclosed.
Beyond the preview
Go deeper on GNS-211-D.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GNS-211-D.